4DMedical (ASX:4DX) Is Down 11.0% After A$79m CT:VQ™ Funding Round Has The Bull Case Changed?

Simply Wall St.

Jan 28

In mid-January 2026, 4DMedical Limited completed a follow-on equity offering of A$79.06 million, issuing 20,806,185 new ordinary shares at A$3.80 each, after holding a special call to explain the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2606799784"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606799784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606799784?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-01-28 14:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606799784","market":"nz","top_or_hot":-1,"title":"4DMedical (ASX:4DX) Is Down 11.0% After A$79m CT:VQ™ Funding Round Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>In mid-January 2026, 4DMedical Limited completed a follow-on equity offering of A$79.06 million, issuing 20,806,185 new ordinary shares at A$3.80 each, after holding a special call to explain the ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-is-down-110-after-a79m-ctvq-funding-round-h\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4DMedical (ASX:4DX) Is Down 11.0% After A$79m CT:VQ™ Funding Round Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4DMedical (ASX:4DX) Is Down 11.0% After A$79m CT:VQ™ Funding Round Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-28 14:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-is-down-110-after-a79m-ctvq-funding-round-h><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In mid-January 2026, 4DMedical Limited completed a follow-on equity offering of A$79.06 million, issuing 20,806,185 new ordinary shares at A$3.80 each, after holding a special call to explain the ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-is-down-110-after-a79m-ctvq-funding-round-h\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"4DX.AU","symbol_name":"4DMEDICAL LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-is-down-110-after-a79m-ctvq-funding-round-h","article_id":"2606799784","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-is-down-110-after-a79m-ctvq-funding-round-h","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606799784","pubTimestamp":1769581322,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In mid-January 2026, 4DMedical Limited completed a follow-on equity offering of A$79.06 million, issuing 20,806,185 new ordinary shares at A$3.80 each, after holding a special call to explain the capital raise.\nThe company highlighted that the funds from this institutional placement will support the U.S. rollout of its CT:VQ™ lung imaging product, expand deployments in leading hospitals, and further its software-based respiratory imaging research efforts.\nWe will now examine how this...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"4DX.AU":"4DMEDICAL LTD","AI":"C3.ai, Inc.","BK4543":"AI","BK4587":"ChatGPT概念","BK7094":"医疗保健技术","BK4551":"寇图资本持仓","BK4588":"碎股","BK4528":"SaaS概念","BK4585":"ETF&股票定投概念","BK4023":"应用软件"},"translate_title":"4DMedical(ASX：4DX)股价下跌11.0%，价值7900万澳元CT：VQ™融资轮牛市情况发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"4DX.AU":1.5,"AI":0.62},"content_text":"In mid-January 2026, 4DMedical Limited completed a follow-on equity offering of A$79.06 million, issuing 20,806,185 new ordinary shares at A$3.80 each, after holding a special call to explain the capital raise. The company highlighted that the funds from this institutional placement will support the U.S. rollout of its CT:VQ™ lung imaging product, expand deployments in leading hospitals, and further its software-based respiratory imaging research efforts. We will now examine how this sizeable capital raise to accelerate CT:VQ™ adoption in the U.S. shapes 4DMedical’s broader investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.AdvertisementWhat Is 4DMedical's Investment Narrative?To own 4DMedical, you really have to believe that software-based lung imaging can move from niche to routine use in large markets like the U.S., and that CT:VQ™ can sit at the center of that shift. The latest A$79.06 million institutional placement materially changes the near-term picture: it gives the company more room to fund the CT:VQ™ rollout, deepen hospital relationships and keep investing in research without relying as heavily on near-term revenue, but it also adds to an already heavy pattern of equity issuance in a business that remains loss-making with limited sales. In the short term, key catalysts still hinge on meaningful U.S. hospital uptake and execution of distribution partnerships, while the biggest risks remain ongoing cash burn, potential further dilution and the challenge of converting technical validation into sustained commercial demand. However, investors should not overlook how repeated capital raises affect their ownership over time.\n\nOur comprehensive valuation report raises the possibility that 4DMedical is priced higher than what may be justified by its financials.Exploring Other PerspectivesASX:4DX 1-Year Stock Price Chart The Simply Wall St Community’s nine fair value views on 4DMedical span from A$0.36 to A$4.25, reflecting very different expectations. Set against a recent A$79.06 million raise to fund CT:VQ™ expansion, that spread underlines how differently people weigh dilution risk versus the opportunity in U.S. hospital adoption.Explore 9 other fair value estimates on 4DMedical - why the stock might be worth less than half the current price!Build Your Own 4DMedical NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your 4DMedical research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.Our free 4DMedical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 4DMedical's overall financial health at a glance.Curious About Other Options?Our daily scans reveal stocks with breakout potential. Don't miss this chance:The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Uncover the next big thing with financially sound penny stocks that balance risk and reward.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}